Vaginal Dryness in Perimenopause and Menopause

In a Nutshell

Vaginal dryness is one of the most common and under-reported symptoms of menopause. It's caused by estrogen decline thinning the vaginal lining, reducing natural lubrication, and changing the local pH.

Unlike hot flashes, it tends to worsen over time without treatment.

Highly effective treatments exist: over-the-counter moisturizers and lubricants, low-dose vaginal estrogen (which generally results in minimal systemic absorption), prasterone (DHEA), and ospemifene. Many women notice improvement within several weeks, with fuller benefit often at 8-12 weeks ¹, ² depending on symptom severity and treatment used.

What Vaginal Dryness Feels Like

Most women first notice vaginal dryness during sex — what used to be naturally lubricated now feels dry, tight, or friction-filled. The discomfort doesn't always stay limited to intercourse. Many women describe persistent vaginal or vulvar burning, itching, or rawness that occurs throughout the day, regardless of sexual activity.

Other common symptoms in the GSM cluster:

• A sensation of pressure, irritation, or "rawness" in the vagina or vulva
• Painful penetration (dyspareunia) — sometimes with light bleeding or "spotting" after sex. Light spotting can occur with fragile atrophic tissue, but any bleeding after menopause — including bleeding after sex — should be evaluated by a clinician
• Vulvar itching or burning
• Vaginal discharge that's thinner, more watery, or sometimes yellow-tinged
• Some women also notice urinary urgency, frequency, burning with urination, recurrent UTIs, or worsening urinary leakage with cough, laugh, or exercise

A key emotional reality this list misses: vaginal dryness changes intimate relationships. Many women begin avoiding sex, lose interest, or feel a quiet grief about the change. Physicians who don't ask about this miss the most distressing part of the symptom.

The first sign is usually reduced natural lubrication during arousal. The condition almost always progresses without treatment — vaginal tissue continues to thin, blood flow continues to decline, and symptoms worsen over months to years.

Why Vaginal Dryness Happens in Menopause

Vaginal tissue is exquisitely estrogen-dependent. As ovarian estrogen production declines through perimenopause and menopause:

• The vaginal lining becomes thinner, less elastic, and more fragile, with reduced glycogen content
• Blood flow to the vaginal walls decreases, reducing the body's ability to produce lubricating transudate during arousal
• The vaginal pH rises from ~3.5–4.5 (acidic) to >4.5–5.5 (less acidic) ¹, which disrupts the protective lactobacilli community and increases susceptibility to bacterial vaginosis and UTIs
• The vaginal canal can become less elastic and, in some women, somewhat narrower or shorter over time
• The vulva also atrophies — the labia minora shrink, the clitoral hood may retract, and the introitus (vaginal opening) narrows
• Production of natural mucus decreases

This is why vaginal dryness behaves differently from hot flashes. Hot flashes typically peak in the first few years post-menopause and then improve. Vaginal dryness tends to worsen progressively without treatment — the longer the tissue is estrogen-deprived, the more atrophic it becomes.

Other (non-menopause) contributors to vaginal dryness include breastfeeding, certain birth control pills, anti-estrogen medications (tamoxifen, aromatase inhibitors used in breast cancer treatment), chemotherapy, ovary removal (oophorectomy), Sjögren's syndrome and other autoimmune conditions, smoking, and some allergy medications and antidepressants.

Regular vaginal stretching or sexual activity may help maintain comfort and elasticity for some women, but a lack of sexual activity is not a personal failure and should not be framed as the cause of GSM.

Is This Normal? When to See a Doctor

Yes, vaginal dryness is biologically expected as estrogen declines — but it's also the most under-reported and under-treated menopause symptom. Harvard Medical School calls out that 50% of postmenopausal women have vaginal dryness, irritation, or pain with sex — and most women don't bring it up to their doctor. Many wait years, assuming nothing can be done.

There's no clinical benefit to waiting. Earlier treatment is easier and more effective than reversing severe long-standing atrophy.

Clinical Red Flags — Do NOT Assume It's Just Menopause

Vaginal dryness is overwhelmingly caused by estrogen deficiency, but several other conditions cause similar or overlapping symptoms. Seek evaluation if you have:

• Bleeding after 12 months without a period — postmenopausal bleeding always needs evaluation, even if it seems related to dryness or sex
• Persistent vaginal discharge that's foul-smelling, frothy, or chunky — possible bacterial vaginosis, trichomoniasis, or candida
• Vulvar lesions, ulcers, or non-healing sores — possible lichen sclerosus, lichen planus, or vulvar precancer
• A discrete lump or thickened area on the vulva
• Pelvic pain that's constant or unrelated to sex — possible pelvic inflammatory disease, endometriosis, or other pathology
• New pain at the vaginal opening that's localized to one specific spot — possible vulvodynia or vestibulodynia, which has different treatment
• Burning that worsens with topical estrogen — possible contact reaction to the vehicle (cream base) or unrelated dermatologic condition

GSM is usually diagnosed based on symptoms and pelvic exam. Vaginal pH testing (>4.5) may support the diagnosis, and a urinalysis or vaginal swab may be used when infection is a concern. Do not self-treat new postmenopausal bleeding with vaginal estrogen until the bleeding has been evaluated.

What You Can Do About It

There's a clear treatment hierarchy. Most women start at the bottom of the ladder and step up if needed.

Quick Reference: Local GSM Treatment Comparison

First line — over-the-counter moisturizers and lubricants

These are different products with different jobs:

• Vaginal moisturizers (Replens®, Hyalo Gyn®, Revaree®, RepHresh®) are applied every 1-3 days. They adhere to the vaginal tissue and help cells retain moisture. They treat the baseline dryness, not just sexual discomfort. Hyaluronic acid suppositories (Hyalo Gyn®, Revaree®) are highly effective non-hormonal options — hyaluronic acid binds water to the vaginal tissue and is one of the most-evaluated alternatives to local estrogen.
• Vaginal lubricants (Astroglide®, K-Y®, Sliquid®, Good Clean Love®) are applied just before sex to reduce friction. They're short-acting.

Composition matters. A 2015 peer-reviewed review found that some popular OTC products have osmolality (concentration) and pH that can damage delicate atrophic tissue with repeated use. WHO recommends lubricants with osmolality below 1,200 mOsm/kg ³ and pH between 4.0 and 4.5. Iso-osmolar, glycerin-free, paraben-free products are gentlest.

• Water-based: most common, easy cleanup, compatible with condoms and silicone toys
• Silicone-based: longer-lasting and often helpful for significant dryness; may not be compatible with some silicone toys, so check manufacturer guidance
• Oil-based: very moisturizing but breaks down latex condoms — not safe with latex barrier methods

For many women in early or mild GSM, OTC products alone are enough.

Second line — local (vaginal) hormone therapy

When OTC isn't sufficient, low-dose vaginal estrogen is the gold standard. Available as:

• Bioidentical vaginal estradiol cream (Estrace® or generic estradiol cream) — applied with applicator, typically nightly for 2-3 weeks then 2-3 times per week. Conjugated equine estrogens (Premarin®) are also FDA-approved for this indication but are not bioidentical; concierge BHRT practices generally prefer estradiol
• Vaginal estradiol tablets (Vagifem®, Yuvafem®, Imvexxy®) — small tablets inserted with applicator, similar tapering schedule
• Vaginal estradiol ring (Estring®) — flexible ring placed in the vagina, releases low-dose estrogen continuously for 3 months
• Compounded bioidentical local therapies — concierge BHRT practices may also prescribe customized compounded vaginal preparations (for example, estradiol with topical testosterone, or estriol/hyaluronic acid blends) when commercial products aren't tolerated or targeted multi-hormone support is needed

Critical safety point: Low-dose vaginal estrogen has minimal systemic absorption, with little to no clinically meaningful increase in blood estrogen levels. The major medical societies — including the North American Menopause Society and ACOG — consider it an option for many women when nonhormonal measures aren't enough.

For breast cancer survivors — especially those on aromatase inhibitors, where non-hormonal methods (lubricants, hyaluronic acid suppositories, vaginal moisturizers) are highly preferred as first-line therapy — treatment should be individualized through shared decision-making with the oncology team.

The boxed warning on these products is a class-wide regulatory artifact and is not a reflection of the local-therapy safety profile, but it is one reason coordinated decision-making matters.

Other targeted treatments

• Prasterone / DHEA (Intrarosa®) ⁴ — a daily vaginal insert containing dehydroepiandrosterone (DHEA), which is converted within vaginal cells into active sex steroids locally, with minimal systemic exposure. Effective for moderate-severe dyspareunia. FDA-approved for painful sex due to GSM
• Ospemifene (Osphena®) ⁵ — a daily oral selective estrogen receptor modulator (SERM) — meaning it has estrogen-like effects in some tissues (including vaginal tissue) while having different effects in others. FDA-approved for moderate-severe dyspareunia. Carries an FDA boxed warning for endometrial cancer and increased risk of blood clots; contraindicated in women with breast cancer history, undiagnosed vaginal bleeding, or VTE history
• Systemic HRT — for women who need treatment for hot flashes, night sweats, or sleep alongside GSM, systemic estrogen treats both. Less appropriate for women whose only symptom is vaginal dryness
• Vaginal CO2 laser and other energy-based devices (MonaLisa Touch™ and similar) — marketed for GSM, but evidence is mixed (sham-controlled trials have not consistently shown benefit), long-term safety data are limited, and these treatments are not FDA-approved specifically for GSM — the FDA has issued safety communications about devices marketed for "vaginal rejuvenation"
• Vaginal dilators — useful for women whose vagina has narrowed; gradual progressive dilation restores comfortable penetrative function
• Pelvic floor physical therapy — long-term vaginal dryness and painful sex frequently lead to pelvic floor muscle hypertonicity (the body learns to brace in anticipation of pain). Restoring tissue health with estrogen alone won't fix this muscle component. A specialized pelvic floor PT can release the protective tension that keeps pain present even after tissue heals.

Lifestyle factors that genuinely help

• Continue penetrative or solo sexual activity if comfortable — increases blood flow and helps maintain tissue elasticity
• Don't use harsh soaps or douches in the vulva or vagina — both disrupt the delicate microbiome and worsen irritation
• Stop smoking — smoking accelerates estrogen loss and worsens GSM
• Stay sexually active with adequate lubrication — reduces severity of atrophy progression

Get Started with JumpstartMD

Vaginal dryness is the most under-treated menopause symptom — and the most progressive without treatment.

JumpstartMD's perimenopause and menopause care is part of our broader Total Health Optimization approach — a medically-supervised bioidentical hormone therapy program delivered by an expert team of licensed clinicians (under physician oversight), supported by lifestyle coaching for the behavioral side of care. Treatment balances five key hormones — estrogen, progesterone, DHEA, testosterone, and thyroid — through pills, creams, patches, injections, or subcutaneous pellet therapy (in-person visits only).

The program follows a structured pathway: a phone connection with our team, an online health questionnaire, comprehensive hormone labs at Quest Laboratories, a clinical consultation to review results, a personalized treatment plan, and regular follow-ups to fine-tune dosing as your body responds. Care is delivered in-person at our 14 California clinics or online from anywhere in California. When weight or metabolic health is contributing to your symptoms, BHRT is coordinated with our medical weight loss program in the same care plan.

Membership benefits include comprehensive lab testing, ongoing support and monitoring, exclusive member pricing on products, and concierge medical insurance claims assistance for PPO out-of-network plans (FSA/HSA accepted).

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.